The Lynx Group
Cholangiocarcinoma News

Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy

Web Exclusives — May 28, 2020

In patients with locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin, although mFOLFOX has been proven to be superior to active symptom control in the ABC-06 trial.1 Irinotecan is an active drug in other gastrointestinal cancers. This phase 2 study evaluated whether mFOLFIRI was superior to mFOLFOX in second-line treatment of patients with BTC.2

Patients diagnosed with BTC with disease progression after prior gemcitabine/cisplatin were randomized (1:1) to either mFOLFOX or mFOLFIRI. Randomization was stratified by tumor location (intrahepatic vs extrahepatic vs gallbladder vs ampulla of vater) and ECOG performance status (0, 1 vs 2). The primary end point was the overall survival (OS) rate at 6 months.

A total of 120 patients were enrolled in this study and 114 patients were treated (mFOLFOX: 56, mFOLFIRI: 58). The median age was 63 years. Most patients had ECOG 0/1 (89.5%). Tumor location was intrahepatic in 47 patients (41.2%), extrahepatic in 27 (23.7%), gallbladder in 35 (30.7%), and ampulla of vater in 5 (4.4%).

At the median follow-up duration of 25.8 months, the 6-month OS rate was 54.2% and 43.6% in the mFOLFOX and mFOLFIRI groups, respectively. Of 101 evaluable patients (mFOLFOX: 51, mFOFIRI: 50), the objective response rate and disease control rate were 5.9% and 66.7% with mFOLFOX and 4.0% and 64.4% with mFOLFIRI, respectively. Median progression-free survival was 2.8 months with mFOLFOX and 2.1 months with mFOLFIRI (P = .887). Median OS was 6.3 months with mFOLFOX and 5.7 months with mFOLFIRI (P = .472). The most common grade 3/4 adverse events were neutropenia (25.0%) and AST/ALT elevation (16.1%) in the mFOLFOX group and neutropenia (25.9%) and anemia (17.2%) in the mFOLFIRI group. Peripheral neuropathy (37.5%) and thrombocytopenia (37.5%) occurred more frequently in the mFOLFOX group, and vomiting (19.0%) and cholangitis (10.3%) occurred more frequently with mFOLFIRI. No chemotherapy-related deaths were reported.

The authors concluded that the mFOLFIRI regimen was tolerable but not superior to mFOLFOX as second-line therapy for BTC. ClinicalTrials.gov number NCT03464968.

References

  1. Lamarca A, et al. J Clin Oncol. 2019;37(15 suppl): Abstract 4003.
  2. Kim JW, et al. ASCO 2020. Abstract 4603.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: